Dr. Iris Grossman

Iris-Grossman

Dr. Iris Grossman

Vice President, Head of Personalized & Predictive Medicine and Analytics Big Data, Teva. Dr. Iris Grossman, VP, Global Head of the Personalized & Predictive Medicine and Analytics Big Data (PPM-ABD) unit for Teva Global R&D, has dedicated her research career (industry and academia) to the advancement of personalized medicine. She is currently charged with defining and implementing the global PPM-ABD strategy for Teva R&D, a leading global pharmaceutical company, covering discovery development and repurposing programs. In 2013, Globes Magazine – Israel’s leading financial magazine, coined Dr. Grossman one of Israel’s top 40 professionals under the age of 40 . Prior to joining Teva, Dr. Grossman was CEO and president of the pharmacogenetics management consultancy IsraGene Ltd., providing services to both the pharma and biotech sectors. This followed several years of spearheading pipeline pharmacogenetic programs for industry and academia as director of pharmacogenetics at Cabernet Pharmaceuticals Inc. Dr. Grossman moved into consultancy having been responsible for running large-scale pharmacogenetic programs at GlaxoSmithKline, with an emphasis on infectious and neurological diseases. In academia, Dr. Grossman was a key member of Professor David Goldstein’s team at the Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, at Duke University. Dr. Grossman received her PhD from the Technion – Israel Institute of Technology, where her research project, conducted in collaboration with the Weizmann Institute for Science, investigated pharmacogenetic markers of multiple sclerosis treatment response.